FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4320912661> ?p ?o ?g. }

• W4320912661 endingPage "100597" @default.
• W4320912661 startingPage "100597" @default.
• W4320912661 abstract "Brain metastases are common in patients with advanced melanoma. This study describes 12-month quality of life (QoL) trajectories following local management of 1-3 melanoma brain metastases.This study assessed QoL data collected during a multi-center, prospective, open-label, phase III randomized controlled trial comparing the efficacy of adjuvant whole brain radiotherapy (WBRT) with observation after local treatment of 1-3 melanoma brain metastases. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Core (QLQ-C30) and Brain Tumour (BN-20) questionnaires at baseline and every 2 months, for 12 months.Using growth mixture modelling, QoL trajectories were identified for global health status, QLQ-C30 and BN-20 subscales for patients with baseline and at least one follow-up assessment. Multivariable logistic regression was used to examine associations between trajectories, demographic, and clinical factors.After combining QoL data from observation and WBRT arms, QLQ-C30 and BN-20 trajectories were calculated for 139 and 137 patients respectively. Depending on the QoL domain, 9-54 % of patients reported a deterioration in QoL. Older age (≥65 years) was significantly associated with deterioration in global health status (OR = 2.88, 95 %CI = 1.27-6.54), physical (OR = 3.49, 95 %CI = 1.29-9.41), role (OR = 4.15, 95 %CI = 1.77-9.71), social (OR = 4.42, 95 % CI = 1.57-12.46), cognitive (OR = 6.70, 95 % CI = 1.93-23.29) and motor functioning (OR = 4.95, 95 %CI = 1.95-12.61) and increased future uncertainty (OR = 0.20, 95 %CI = 0.07-0.53). Female sex (OR = 0.10, 95 %CI = 0.02-0.41), not having neurosurgery at baseline (OR = 0.09, 95 %CI = 0.02-0.52), 2-3 brain metastases (OR = 5.75, 95 %CI = 1.76-18.85) or receiving adjuvant WBRT (OR = 6.77, 95 %CI = 2.00-22.99) were associated with poorer physical, emotional, cognitive and social outcomes respectively.Poorer QoL outcomes in the first 12 months after diagnosis of melanoma brain metastases were observed in patients aged ≥ 65 years, females, having 2-3 brain metastases, non-surgical treatment of metastases or adjuvant WBRT.Clinical Trial Registration Number:Whole Brain Radiotherapy Trial (WBRTMel) was registered with the Australian Clinical Trials Registry (ACTRN12607000512426) and ClinicalTrials.gov (NCT01503827).Study Support:This project was funded by Cancer Australia PdCCRS (Grants No. 512358, 1009485, and 1084046) and the National Helath and Medical Research Coucil of Australia (NHMRC; Grant No. 1135285).ADT was supported by a Cancer Australia Priority-driven Collaborative Cancer Research Scheme. Project #1046923. RLM was supported by an NHMRC Fellowship #1194703 and a University of Sydney, Robinson Fellowship. JFT was supported by an NHMRC Program Grant #1093017." @default.
• W4320912661 created "2023-02-16" @default.
• W4320912661 creator A5012333085 @default.
• W4320912661 creator A5022375432 @default.
• W4320912661 creator A5034265780 @default.
• W4320912661 creator A5034982958 @default.
• W4320912661 creator A5035263718 @default.
• W4320912661 creator A5036987287 @default.
• W4320912661 creator A5040969461 @default.
• W4320912661 creator A5046891733 @default.
• W4320912661 creator A5061349309 @default.
• W4320912661 creator A5064952058 @default.
• W4320912661 creator A5083307021 @default.
• W4320912661 creator A5090390499 @default.
• W4320912661 date "2023-07-01" @default.
• W4320912661 modified "2023-09-25" @default.
• W4320912661 title "Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial" @default.
• W4320912661 cites W1931544110 @default.
• W4320912661 cites W1947168884 @default.
• W4320912661 cites W1965397926 @default.
• W4320912661 cites W1977733462 @default.
• W4320912661 cites W1990448665 @default.
• W4320912661 cites W1993621543 @default.
• W4320912661 cites W2020564169 @default.
• W4320912661 cites W2027971930 @default.
• W4320912661 cites W2055656744 @default.
• W4320912661 cites W2072044537 @default.
• W4320912661 cites W2096313377 @default.
• W4320912661 cites W2098677385 @default.
• W4320912661 cites W2110349527 @default.
• W4320912661 cites W2111521308 @default.
• W4320912661 cites W2121051049 @default.
• W4320912661 cites W2132579916 @default.
• W4320912661 cites W2135001286 @default.
• W4320912661 cites W2167571044 @default.
• W4320912661 cites W2528687466 @default.
• W4320912661 cites W2743961229 @default.
• W4320912661 cites W2747585789 @default.
• W4320912661 cites W2757095060 @default.
• W4320912661 cites W2806969608 @default.
• W4320912661 cites W2895164590 @default.
• W4320912661 cites W2898633044 @default.
• W4320912661 cites W2908877869 @default.
• W4320912661 cites W2940335556 @default.
• W4320912661 cites W2964429012 @default.
• W4320912661 cites W2969314258 @default.
• W4320912661 cites W2981568008 @default.
• W4320912661 cites W2990928375 @default.
• W4320912661 cites W3005704292 @default.
• W4320912661 cites W3008879128 @default.
• W4320912661 cites W3019368013 @default.
• W4320912661 cites W3024501588 @default.
• W4320912661 cites W3025292620 @default.
• W4320912661 cites W3041853066 @default.
• W4320912661 cites W3047382685 @default.
• W4320912661 cites W3098804274 @default.
• W4320912661 cites W3186387320 @default.
• W4320912661 cites W4200190043 @default.
• W4320912661 cites W4200214121 @default.
• W4320912661 cites W4306915041 @default.
• W4320912661 cites W4375816008 @default.
• W4320912661 cites W2594787709 @default.
• W4320912661 doi "https://doi.org/10.1016/j.ctro.2023.100597" @default.
• W4320912661 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37441544" @default.
• W4320912661 hasPublicationYear "2023" @default.
• W4320912661 type Work @default.
• W4320912661 citedByCount "0" @default.
• W4320912661 crossrefType "journal-article" @default.
• W4320912661 hasAuthorship W4320912661A5012333085 @default.
• W4320912661 hasAuthorship W4320912661A5022375432 @default.
• W4320912661 hasAuthorship W4320912661A5034265780 @default.
• W4320912661 hasAuthorship W4320912661A5034982958 @default.
• W4320912661 hasAuthorship W4320912661A5035263718 @default.
• W4320912661 hasAuthorship W4320912661A5036987287 @default.
• W4320912661 hasAuthorship W4320912661A5040969461 @default.
• W4320912661 hasAuthorship W4320912661A5046891733 @default.
• W4320912661 hasAuthorship W4320912661A5061349309 @default.
• W4320912661 hasAuthorship W4320912661A5064952058 @default.
• W4320912661 hasAuthorship W4320912661A5083307021 @default.
• W4320912661 hasAuthorship W4320912661A5090390499 @default.
• W4320912661 hasBestOaLocation W43209126611 @default.
• W4320912661 hasConcept C126322002 @default.
• W4320912661 hasConcept C151956035 @default.
• W4320912661 hasConcept C159110408 @default.
• W4320912661 hasConcept C168563851 @default.
• W4320912661 hasConcept C203092338 @default.
• W4320912661 hasConcept C2777658100 @default.
• W4320912661 hasConcept C2779951463 @default.
• W4320912661 hasConcept C502942594 @default.
• W4320912661 hasConcept C509974204 @default.
• W4320912661 hasConcept C535046627 @default.
• W4320912661 hasConcept C71924100 @default.
• W4320912661 hasConceptScore W4320912661C126322002 @default.
• W4320912661 hasConceptScore W4320912661C151956035 @default.
• W4320912661 hasConceptScore W4320912661C159110408 @default.
• W4320912661 hasConceptScore W4320912661C168563851 @default.
• W4320912661 hasConceptScore W4320912661C203092338 @default.
• W4320912661 hasConceptScore W4320912661C2777658100 @default.

• next